摘要
目的观察健脾散结方联合载药微球栓塞治疗中晚期肝癌的临床疗效。方法纳入医院2021年8月—2022年12月住院的中晚期肝癌患者60例,按照随机数字表法分为两组,对照组30例进行载药微球栓塞治疗,观察组30例采用健脾散结方联合载药微球栓塞治疗。比较分析两组患者的实体瘤客观疗效,症状改善率,体质量变化和卡诺夫斯基健康状况量表(Karnofsky performance scores, KPS)评分,肿瘤标志物甲胎蛋白(alpha-fetoprotein, AFP)、糖类抗原199(carbohydrate antigen 199,CA199)、糖类抗原125(carbohydrate antigen 125,CA125)的变化以及不良反应发生情况。结果两组患者实体瘤客观疗效比较,观察组、对照组有效率分别为83.33%(25/30)、66.67%(22/30),差异无统计学意义(P>0.05),观察组、对照组稳定率分别为96.67%(29/30)、73.33%(22/30),观察组显著高于对照组,差异有统计学意义(P<0.05)。观察组、对照组症状改善率分别为93.33%(28/30)、70.00%(21/30),观察组显著高于对照组,差异有统计学意义(P<0.05)。观察组和对照组体质量变化情况比较,差异无统计学意义(P>0.05)。治疗后两组患者KPS评分均显著增高(P<0.05),并且观察组显著高于对照组[(71.31±9.22)分vs (64.54±7.26)分](P<0.05)。观察组患者肿瘤标志物AFP、CA199、CA125水平降低更显著,与对照组比较差异有统计学意义[(29.72±6.34)μg/L、(34.08±3.10)U/mL、(127.71±29.65)kU/L vs (34.08±5.26)μg/L、(37.67±4.35)U/mL、(156.83±27.54)kU/L](P<0.05)。观察组不良反应发生情况优于对照组,差异有统计学意义(P<0.05)。结论健脾散结方联合载药微球栓塞治疗中晚期肝癌能够更好地抑制肿瘤病灶的生长、改善患者的临床症状、提高疗效,并且安全性良好,为中西医结合治疗中晚期肝癌提供了可行的思路、方法及指导依据。
Objective To observe the clinical effect of Jianpi Sanjie Decoction(健脾散结方)combined with drug-loaded microsphere embolization in the treatment of advanced liver cancer.Methods Sixty patients with advanced liver cancer who were hospitalized in the hospital from August 2021 to December 2022 were divided into two groups according to the random number table method.Thirty patients in the control group were treated with drug-loaded microsphere embolization,and the other 30 patients in the observation group were treated with Jianpi Sanjie Decoction combined with drug-loaded microsphere embolization.The objective efficacy of solid tumors,symptom improvement rate,weight change and Karnovsky health status scale(KPS)score,the changes of tumor markers alpha-fetoprotein(AFP),carbohydrate antigen 199(CA199)and carbohydrate antigen 125(CA125)and adverse reactions were compared between the two groups.Results The effective rates of the observation group and the control group were 83.33%(25/30)and 66.67%(22/30),and the difference was not statistically significant(P>0.05).The stability rates of the observation group and the control group were 96.67%(29/30)and 73.33%(27/30),respectively.The rate of the observation group was significantly higher than that of the control group(P<0.05).The symptom improvement rates of the observation group and the control group were 93.33%(28/30)and 70.00%(21/30),respectively.The symptom improvement rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in weight change between the observation group and the control group(P>0.05).After treatment,the KPS scores of the two groups were significantly increased(P<0.05),and the score of the observation group was significantly higher than that of the control group[(71.31±9.22)points vs(64.54±7.26)points](P<0.05).The levels of tumor markers AFP,CA199 and CA125 in the observation group were significantly lower than those in the control group[(29.72±6.34)μg/L,(34.08±3.10)U/mL,(127.71±29.65)kU/L vs(34.08±5.26)μg/L,(37.67±4.35)U/mL,(156.83±27.54)kU/L](P<0.05).The incidence of adverse reactions in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Jianpi Sanjie Decoction combined with drug-loaded microsphere embolization in the treatment of advanced liver cancer can better inhibit the growth of tumor lesions,improve the clinical symptoms and the curative effect,and has good safety.It provides feasible ideas,methods and guidance for the treatment of advanced liver cancer with integrated traditional Chinese and Western medicine.
作者
张金忠
朱冬霞
李富永
郭晓青
亓久德
谭国柱
ZHANG Jinzhong;ZHU Dongxia;LI Fuyong;GUO Xiaoqing;QI Jiude;TAN Guozhu(People's Hospital Affiliated to Shandong First Medical University,Jinan City People's Hospital,Jinan 271119,Shandong,China)
出处
《中华中医药学刊》
CAS
北大核心
2024年第7期218-221,共4页
Chinese Archives of Traditional Chinese Medicine
基金
山东省中医药科技发展计划项目(2019-0573)
山东省老年医学学会科技攻关计划项目(LKJGG2021W057)。
关键词
肝癌
中晚期
健脾散结方
载药微球栓塞
疗效
生活质量
肿瘤标志物
不良反应
liver cancer
advanced
Jianpi Sanjie Decoction(健脾散结方)
drug-loaded microsphere embolization
curative effect
quality of life
tumor markers
adverse reactions
作者简介
张金忠(1984-),男,山东莱芜人,主治医师,硕士,研究方向:肿瘤的中西医结合治疗。
